Pathophysiology, causes and epidemiology of chronic heart failure
Authors:
Jindřich Špinar 1; Lenka Špinarová 2; Jiří Vítovec 2
Authors‘ workplace:
Interní kardiologická klinika LF MU a FN Brno, pracoviště Bohunice
1; I. interní kardio-angiologická klinika LF MU a FN u sv. Anny v Brně
2
Published in:
Vnitř Lék 2018; 64(9): 834-838
Category:
Reviews
Overview
The prevalence of heart failure in developed countries is about 1–2 % in general and in patients above 70 years over 10 %. HFpEF is the cause of heart failure from 22 to 73 %, exact data are not available. If compared with HFrEF, patients with HFpEF are older, more frequent women with hypertension and atrial fibrillation, but less myocardial infarction in their history. Heart failure is a hemodynamic disorder and the pathophysiologic basis is cardiac output, cardiac contractility, filling pressures, wall stress during systolic and diastolic function and heart rate. The neurohumoral activation is very important for the diagnosis as well as prognosis and the most sensitive seems to be brain natriuretic peptide (BNP), respectively the precursor NT-proBNP, which become a part of the new diagnostic classification and are a part of modern treatment.
Key words:
heart failure – hemodynamics – neurohumoral activation
Sources
- Ponikowski P, Voors AA, Anker SD et al. [ESC Scientific Document Group]. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129–2200. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw128>. Erratum in Erratum. [Eur Heart J. 2018].
- Antman EM, Bax J, Chazal RA. Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. Eur Heart J. 2016; 37(27): 2096. Dostupné z DOI: <http://doi: 10.1093/eurheartj/ehw219>.
- Špinar J, Hradec J, Špinarová L et al. Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Prepared by the Czech Society of cardiology. Cor Vasa 2016; 58(5): e530-e568. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crvasa.2016.09.004>.
- Špinar J, Hradec J, Špinarová L et al. Souhrn doporučených postupů ESC pro diagnózu a léčbu akutního a chronického srdečního selhání z roku 2016. Připraven Českou kardiologickou společností. Cor et Vasa 2016; 58(5): 455–494.
- Špinar J, Špinarová L. Chronické srdeční selhání. In: Táborský M. Novinky v kardiologii. Mladá fronta: Praha 2015: 212–229. ISBN 978–80–204–3712–9.
- Tanai E, Frantz S. Pathophysiology of Heart Failure. Compr Physiol 2015; 6(1): 187–214. Dostupné z DOI: <http://dx.doi.org/10.1002/cphy.c140055>.
- Widimský J, Lefflerová K, Sedlacek K. Srdeční selhání. 4. vyd. Triton: Praha 2013. ISBN 978–80–7387–680–7.
- Petrie MC, McClure SJ, Love MP et al. Novel neuropeptide in the pathophysiology of heart failure:adrenomedullin and endothelin-1. Eur J Heart Failure 1999; 1(1): 25–29. Dostupné z DOI: <http://dx.doi.org/10.1016/S1388–9842(98)00013–0>.
- Špinarová L, Toman J, Pospíšilová J et al. Humoral response in patients with chronic heart failure. Int J Cardiol 1998; 65(3): 227–232.
- Pacher R, Stanek B, Huelsman M et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996; 27(3): 633–641.
- Kim HN, Januzzi JL. Natriuretic Peptide Testing in Heart Failure. Circulation 2011; 123(18): 2015–2019. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.110.979500>.
- Cheng V, Kazanegra R, Garcia A et al. A Rapid Bedside Test for B-Type Peptide Predicts Treatment Outcomes in Patients Admitted for Decompensated Heart Failure: A Pilot Study. J Am Coll Cardiol 2001; 37(2): 386–391.
- Maeda K, Tsutamoto T, Wada A et al. High Levels of Plasma Brain Natriuretic Peptide and Interleukin-6 After Optimized Treatment for Heart Failure Are Independent Risk Factors for Morbidity and Mortality in Patients With Congestive Heart Failure. J Am Coll Cardiol 2000; 36(5): 1587–1593.
- Špinarová L, Špinar J, Vítovec J Mají natriuretické peptidy novou šanci v léčbě srdečního selhání? Vnitř Lék 2014; 60(12): 1076–1080.
- Vítovec J, Špinar J, Špinarová L. Inhibice systému renin-angiotensin-aldosteron u srdečního selhání aneb od obecného souhlasu (CONSENSUS) po vzorec myšlení (PARADIGM-HF). Vnitř Lék 2015; 61(5): 470–474.
- Špinarová L, Špinarová M, Goldbergová-Pávková M et al. Prognostic impact of copeptin and mid-regional pro-adrenomedullin in chronic heart failure with regard to comorbidities. Cardiovasc Dis Diagn 2018; 6(4): 326. Dostupné z DOI: <http://dx.doi.org/10.4172/2329–9517.1000326.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2018 Issue 9
Most read in this issue
- Diagnosis of heart failure: the new classification of heart failure
- Pathophysiology, causes and epidemiology of chronic heart failure
- Outpatient treatment of proximal deep vein thrombosis
- What we know about epidemiology of heart failure in Slovakia and globally